620 Per Cent Returns: Multibagger Specialty Chemicals & Pharma Stock To Keep Under Radar As Board Announces Stock Split
The stock gave multibagger returns of 620 per cent from its 52-week low of Rs 58.20 per share.
Today, shares of Sudarshan Pharma Industries Ltd gained 1.61 per cent to an intraday high of Rs 419 per share from its previous closing of Rs 412.35 per share. The stock’s 52-week high is Rs 434 per share while its 52-week low is Rs 58.20 per share.
The Board of Directors of the company approved a sub-division /stock split of the company’s 1 (one) equity share having a face value of R 10 each fully paid-up, into 10 equity shares of the company having a face value of Re 1 each fully paid-up, subject to the approval of shareholders and such other approvals as may be required. The reason behind the split is to enhance the liquidity of the company’s share and to make it more affordable for small investors and also to broaden the company's investor base.
Additionally, the company has expanded its reach with the establishment of a new subsidiary, Sudarshan Maven Pharma Private Limited. The parent company has taken a controlling interest in Sudarshan Maven by acquiring 70 per cent of its equity shares. Sudarshan Maven is primarily focused on the research, development, and manufacturing of pharmaceutical products, including active pharmaceutical ingredients (APIs), intermediates, and antibiotics. The subsidiary also ventures into healthcare products, Ayurvedic supplements, and medicinal preparations. This strategic acquisition aligns seamlessly with Sudarshan Pharma's existing business operations and is anticipated to drive growth and diversification within the chemical and pharmaceutical sectors.
DSIJ’s ‘Micro Marvel' service recommends micro-cap stocks with the potential to grow multifold in long run. If this interests you, do download the service details here.
Sudarshan Pharma Industries Limited (SPIL), established in 2008 and headquartered in Mumbai, is a prominent contract manufacturer of generic formulations. Operating across diverse segments, including specialty chemicals, intermediates, APIs, pharmaceutical and formulation generics, and bulk supply, SPIL caters to a wide range of institutions and healthcare organizations.
Beyond its contract manufacturing services, SPIL has ventured into branded products through its Vimac Healthcare division. A significant portion of its product portfolio, consisting of 56 out of 96 items, is registered under the "R" trademark. Furthermore, SPIL collaborates with renowned Indian companies and institutional clients, offering contract manufacturing services for pharmaceutical formulations and medicines.
The company has a market cap of Rs 970 crore and has delivered good profit growth of 37 per cent CAGR over the last 5 years. The stock gave multibagger returns of 620 per cent from its 52-week low of Rs 58.20 per share. Investors should keep an eye on this micro-cap stock.
Disclaimer: The article is for informational purposes only and not investment advice.